CDCD1; CMD1A; CMT2B1; EMD2; FPL; FPLD; HGPS; IDC; LDP1; LFP; LGMD1B; LMN1; LMNC; PRO1; Cardiomyopathy Dilated 1A; Limb Girdle Muscular Dystrophy 1B; Progeria 1

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit

The antibody is a?Rabbit polyclonal?antibody raised against?LMNA Polyclonal Antibody. It has been selected for its ability to recognize?LMNA Polyclonal Antibody in immunohistochemical staining and western blotting.

Antigen-specific affinity chromatography followed by Protein A affinity chromatography

Liquid

200ug/ml (lot specific)

Store at 4 degree C for frequent use. Aliquot and store at -20 degree C for 12 months.
Avoid repeated freeze/thaw cycles.

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 degree C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Manufactured in an ISO 9001:2008 and ISO 13485:2003 Certified Laboratory.

Manufactured in a lab with traceable raw materials. Bulk orders can typically be prepared to the customera??s specifications, please inquire.

Small volumes of anti-LMNA antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Western Blot (WB)

Loading Control of WB.

lamin A/C

lamin

Prelamin-A/C

LMN1??[Similar Products]

LMNA_HUMAN

The nuclear lamina consists of a two-dimensional matrix of proteins located next to the inner nuclear membrane. The lamin family of proteins make up the matrix and are highly conserved in evolution. During mitosis, the lamina matrix is reversibly disassembled as the lamin proteins are phosphorylated. Lamin proteins are thought to be involved in nuclear stability, chromatin structure and gene expression. Vertebrate lamins consist of two types, A and B. Alternative splicing results in multiple transcript variants. Mutations in this gene lead to several diseases: Emery-Dreifuss muscular dystrophy, familial partial lipodystrophy, limb girdle muscular dystrophy, dilated cardiomyopathy, Charcot-Marie-Tooth disease, and Hutchinson-Gilford progeria syndrome. [provided by RefSeq, Apr 2012]

lamin A/C: nuclear lamins are intermediate filament proteins that constitute the lattice-like matrix at the inner face of the nuclear membrane that underlies the nuclear envelop. The lamins, highly conserved throughout evolution, are encoded by three genes in the human: LMNA, LMNB1, and LMNB2. The A-type lamins (lamin A/C) are developmentally regulated and are generally expressed in differentiated cells. The anchoring of chromatin to the nuclear lamina is involved in the control of gene expression and in DNA replication and repair. During mitosis, the nuclear lamina is reversibly disassembled as the lamin proteins are phosphorylated. Cleaved by caspase-6 during apoptosis into a 40-45 kDa and a28 kDa fragment.

Protein type: Cytoskeletal

Chromosomal Location of Human Ortholog: 1q22

Cellular Component: nucleoplasm; nuclear lamina; nuclear membrane; perinuclear region of cytoplasm; cytoplasm; lamin filament; intermediate filament; nuclear speck; nuclear envelope; nucleus; cytosol

Molecular Function: protein binding; structural molecule activity

Biological Process: muscle development; mitotic nuclear envelope reassembly; apoptosis; unfolded protein response; ventricular cardiac muscle cell development; mitotic nuclear envelope disassembly; regulation of cell migration; cellular protein metabolic process; unfolded protein response, activation of signaling protein activity; sterol regulatory element binding protein nuclear translocation; mitotic cell cycle; cell structure disassembly during apoptosis; establishment and/or maintenance of microtubule cytoskeleton polarity

Disease: Heart-hand Syndrome, Slovenian Type; Emery-dreifuss Muscular Dystrophy 2, Autosomal Dominant; Restrictive Dermopathy, Lethal; Muscular Dystrophy, Congenital, Lmna-related; Mandibuloacral Dysplasia With Type A Lipodystrophy; Emery-dreifuss Muscular Dystrophy 3, Autosomal Recessive; Charcot-marie-tooth Disease, Axonal, Type 2b1; Lipodystrophy, Familial Partial, Type 2; Hutchinson-gilford Progeria Syndrome; Cardiomyopathy, Dilated, 1a; Muscular Dystrophy, Limb-girdle, Type 1b; Cardiomyopathy, Dilated, With Hypergonadotropic Hypogonadism

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.